ClinicalTrials.gg
CompletedNCT03340870Updated Nov 14, 2017

A Study to Evaluate Pharmacokinetics of Sonazoid™ Following Intravenous Bolus Injection in Healthy Volunteers

A Phase 1 interventional study of Sonazoid™ in Healthy, sponsored by GE Healthcare. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-14.

Sponsored by GE Healthcare · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Oct 2014, registered Nov 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The primary purpose of this study is to determine the Pharmacokinetics (PK) data of perfluorobutane (PFB) in blood and exhaled air following intravenous (I.V.) bolus injection of Sonazoid™ in healthy volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

GE Healthcare is the lead sponsor of 176 studies on the registry; 21 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Participants may be included in the study if they meet all of the following criteria:

  • Participant is between 18 and 45 years of age
  • Participant is male, or a female who was either surgically sterile (has a documented bilateral oophorectomy and/or documented hysterectomy), (cessation of menses for more than 1 year), or non-lactating, or if of the results of a serum or urine human chorionic gonadotropin pregnancy test, performed on the day of Sonazoid™ administration (with the result known before IMP administration), were negative
  • Participant is able and willing to comply with study procedures and provide signed and dated
  • Participant has a of 19 to 26
  • Participant has agreed not to smoke from 2 hours before to 5 hours after Sonazoid™ administration
  • Participant has agreed to avoid strenuous physical activity from 1 week before Sonazoid™ administration until the end of the study follow-up
  • Participant has no history of alcohol or substance abuse, and has agreed to no intake of alcohol or drugs for 48 hours before Sonazoid™ administration and until the end of the study follow-up
  • Participant has a normal health status, as judged by medical history and physical examination at screening
  • Normal 12-lead (ECG) at screening. Minor abnormalities considered by the investigator to be of no clinical importance are permitted
  • Normal blood and urine clinical chemistry variables at screening. Isolated or minimally out-of-range values considered by the investigator to be of no clinical importance are permitted
  • No regular use of concomitant medication, except for routine use of supplemental oestrogen

Exclusion Criteria:

  • Participant was previously included in this study
  • Participation in another clinical trial with an unregistered medicinal product, or less than 30 days have passed since completing participation in such a trial
  • Participant has a history of allergies to eggs or egg products (i.e., manifested by full body rash, respiratory difficulty, oral and laryngeal swelling, hypotension or shock)
  • Donation of >500 milliliter (mL) blood in the 12 weeks before Sonazoid™ administration
  • Participant with congenital heart defects, including right-to-left, bi-directional, or transient right-to-left cardiac shunts
  • Participant has positive test results for , , or
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Sonazoid™ 0.12 microliter (µl)

    Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 µl microbubbles (MB)/kilogram (kg) body weight.

    Drug: Sonazoid™

  • Experimental
    Sonazoid™ 0.60 µl

    Participants will receive single I.V bolus injection of Sonazoid™ 0.60 µl MB/kg body weight.

    Drug: Sonazoid™

Interventions

  • Single Dose of Sonazoid™ lipid-stabilised aqueous suspension of perfluorobutane (PFB) gas microbubbles.

    Also known as: perfluorobutane

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Versus Time Curve from Time Zero to the Last Time- Point (AUC 0-last), AUC from Time Zero to Infinity (AUC0-infinity∞) After Single Dose in Blood

    Time frame: Pre dose and at 0.5, 1, 2, 5, 10, 15, 30, 60, 120 minutes and 4 hours post dose

  2. Area Under the Concentration Versus Time Curve from Time Zero to the Last Time- Point (AUC 0-last), AUC from Time Zero to Infinity (AUC0-Infinity∞) After Single Dose in Exhaled Air

    Time frame: Pre dose and at 1, 3, 6, 9, 16, 31, 61, 121 minutes and 4 hours post dose

  3. Percentage of the Extrapolated Area to Total Area (% AUC ext) After Single Dose in Blood

    Time frame: Pre dose and at 0.5, 1, 2, 5, 10, 15, 30, 60, 120 minutes and 4 hours post dose

  4. Percentage of the Extrapolated Area to Total Area (% AUC ext) After Single Dose in Exhaled Air

    Time frame: Pre dose and at 1, 3, 6, 9, 16, 31, 61, 121 minutes and 4 hours post dose

  5. Elimination Rate Constant (kel) in Blood

    Time frame: Pre dose and at 0.5, 1, 2, 5, 10, 15, 30, 60, 120 minutes and 4 hours post dose

  6. Elimination Rate Constant (kel) in Exhaled Air

    Time frame: Pre dose and at 1, 3, 6, 9, 16, 31, 61, 121 minutes and 4 hours post dose

  7. Elimination Half-life (t½) in Blood

    Time frame: Pre dose and at 0.5, 1, 2, 5, 10, 15, 30, 60, 120 minutes and 4 hours post dose

  8. Elimination Half-life (t½) in Exhaled Air

    Time frame: Pre dose and at 1, 3, 6, 9, 16, 31, 61, 121 minutes and 4 hours post dose

  9. Clearance (Cl) in Blood

    Time frame: Pre dose and at 0.5, 1, 2, 5, 10, 15, 30, 60, 120 minutes and 4 hours post dose

  10. Clearance (Cl) in Exhaled Air

    Time frame: Pre dose and at 1, 3, 6, 9, 16, 31, 61, 121 minutes and 4 hours post dose

  11. Maximum Observed Concentration (Cmax) in Blood

    Time frame: Pre dose and at 0.5, 1, 2, 5, 10, 15, 30, 60, 120 minutes and 4 hours post dose

  12. Maximum Observed Concentration (Cmax) in Exhaled Air

    Time frame: Pre dose and at 1, 3, 6, 9, 16, 31, 61, 121 minutes and 4 hours post dose

  13. Time at which Cmax is reached (tmax) in Blood

    Time frame: Pre dose and at 0.5, 1, 2, 5, 10, 15, 30, 60, 120 minutes and 4 hours post dose

  14. Time at which Cmax is reached (tmax) in Exhaled Air

    Time frame: Pre dose and at 1, 3, 6, 9, 16, 31, 61, 121 minutes and 4 hours post dose

  15. Volume of Distribution (Vd) in Blood

    Time frame: Pre dose and at 0.5, 1, 2, 5, 10, 15, 30, 60, 120 minutes and 4 hours post dose

  16. Volume of Distribution (Vd) in Exhaled Air

    Time frame: Pre dose and at 1, 3, 6, 9, 16, 31, 61, 121 minutes and 4 hours post dose

Secondary outcomes

  1. Percentage of Participants With Treatment-Related Adverse Events (AEs)

    Time frame: Up to 72 hours after first administration of investigational medicinal product (IMP)

  2. Percentage of Participants With Abnormal Laboratory Values

    Time frame: Up to 4 hours post dose

  3. Percentage of Participants With Abnormal Vital Signs

    Time frame: Up to 4 hours post dose

  4. Percentage of Participants With Injection Site Reactions

    Time frame: Up to 4 hours post dose

  5. Percentage of Participants With Abnormal Physical Examinations

    Time frame: Up to 4 hours post dose

07

Study locations

1 site
  • Beijing Chao-Yang Hospital, Capital Medical University, NO. 8 Gongren Tiyuchang Nanlu
    Chaoyang, Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in Nov 2014, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2017
First posted
Nov 14, 2017
StartActual
Oct 20, 2014
Primary completionActual
Nov 20, 2014
CompletionActual
Nov 20, 2014
Last update
Nov 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03340870
Lead sponsor
GE Healthcare
Responsible party
Sponsor
First posted
Nov 14, 2017
Start date
Oct 20, 2014
Primary completion
Nov 20, 2014
Completion
Nov 20, 2014
Last update
Nov 14, 2017

Study contacts

Francois Tranquart, MD, PhD
study chair · GE Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonazoid

Start the discussion